A team of researchers has uncovered critical information that could help scientists understand how protein polymers interact with other self-assembling biopolymers. The research helps explain naturally occurring nanomaterial within cells and could one day lead to engineered bio-composites for drug delivery, artificial tissue, bio-sensing, or cancer diagnosis.
Univ. of Michigan researchers are the first to use...
Accelrys Inc. has announced the release of Accelrys Insight and Accelrys Insight for...
According to a recent study published by the National Science Foundation (NSF),...
A study at the Univ. of Utah finds that more than 60% of antibiotic prescriptions are for types that kill multiple kinds of bacteria. Unfortunately, in more than 25% of cases such prescriptions are useless because the infection stems from a virus, which cannot be treated with antibiotics. This overuse of antibiotics has a number of downsides.
Researchers in Texas have discovered a new chemical reaction that has the potential to lower the cost and streamline the manufacture of compounds ranging from agricultural chemicals to pharmaceutical drugs. The reaction resolves a long-standing challenge in organic chemistry in creating phenolic compounds from aromatic hydrocarbons quickly and cheaply.
On Thursday, Sigma-Aldrich Corp.announced a partnership with The Scripps Research Institute (TSRI) to fund research and provide immediate, day-of-publication access to TSRI researchers’ discoveries for the synthesis and analysis of potential drugs. The partnership promises to eliminate months from the translation of cutting-edge chemistry into widespread applications for drug discovery.
New research raises fresh questions about which cancer patients benefit from Avastin, a drug that lost its approval for treating breast cancer nearly two years ago. Two studies found that Avastin did not prolong life when used as a first treatment for people with brain tumors like the one U.S. Sen. Edward Kennedy died of several years ago. Side effects also were more common with Avastin.
British drugmaker GlaxoSmithKline PLC said Wednesday that it will buy Okairos AG for about $323 million, gaining the Swiss vaccine developer's products. GlaxoSmithKline said Okairos is studying vaccine technology that could be used in shots that can both prevent and cure infections or diseases.
Specialty drugmaker Biogen Idec said Tuesday it submitted a new injectable multiple sclerosis drug to the Food and Drug Administration for U.S. market approval. The drug, called Plegridy, is intended to treat patients with relapsing forms of multiple sclerosis.
Shares of XenoPort Inc. sank Monday after the drug developer said a potential treatment for multiple sclerosis patients failed in late-stage clinical testing, and it will stop developing the drug. The Santa Clara, Calif., company said the treatment, labeled arbaclofen placarbil, failed to show a statistically significant improvement for patients taking it compared to a fake drug.
State pharmacy officials on Thursday threw their support behind a proposal giving the Food and Drug Administration authority over large compounding pharmacies, in an effort to head off more outbreaks tied to contaminated medications. The head of the National Association of Boards of Pharmacy told Senate lawmakers that his group welcomes FDA action against pharmacies.
Bristol-Myers Squibb Co. said Friday that U.S. regulators expanded approval of its HIV drug Sustiva to children as young as three months old. The capsule-based drug was first approved in 1998 to treat HIV-infected children who are age three and older and weigh at least 22 pounds. The new approval expands the drug's use to children age three months to three years who weigh at least 7.7 pounds.
U.S. health officials are making a high-tech screening device available to African authorities to help spot counterfeit malaria pills in hopes that the technology may eventually be used to combat the fake drug trade worldwide. The FDA announced Wednesday that regulators in Ghana will begin using a federally developed handheld device to screen for fake or diluted versions of two common malaria pills.
The Food and Drug Administration says it has uncovered potential safety problems at 30 specialty pharmacies that were inspected in the wake of a recent outbreak of meningitis caused by contaminated drugs. The agency said its inspectors targeted 31 compounding pharmacies that produce sterile drugs, which must be prepared under highly sanitary conditions.
BIND Therapeutics said Wednesday that Pfizer Inc. has agreed to pay it $160 million per drug as part of a collaboration to develop targeted medicines using nanotechnology which use particles measured in billionths of a meter. BIND is developing an experimental group of targeted, programmable...
The Food and Drug Administration on Friday approved a first-of-its-kind diabetes drug from Johnson & Johnson that uses a new method to lower blood sugar—flushing it out in patients' urine. The agency cleared J&J's Invokana tablets for adults with Type 2 diabetes, which affects an estimated 26 million Americans. The once-a-day medication works by blocking the kidneys from reabsorbing sugar, which occurs at higher levels in patients with diabetes than in healthy patients.
The Food and Drug Administration has approved a new imaging drug to help doctors locate lymph nodes in patients with breast cancer and skin cancer. The drug Lymphoseek from Navidea Biopharmaceuticals Inc. is a radioactive imaging agent that is intended to help determine if breast cancer or melanoma has spread to a patient's lymph nodes.
Biogen Idec has filed for federal marketing approval of a longer-lasting treatment for hemophilia A. Biogen says the drug rFVIIIFc can be injected once or twice a week, while other treatments for hemophilia A need to be injected three or four times a week. The drug could be the first major advance in the treatment of hemophilia in more than 20 years.
India's patent appeals office has rejected Bayer AG's plea to stop the production of a cheaper generic version of a patented cancer drug in a ruling that health groups say is an important precedent for getting inexpensive lifesaving medicines to the poor. Bayer sells a one month supply of the drug for about $5,600. Natco's version would cost Indian patients $175 a month, less than 1/30th as much.
Pharmaceutical residues in water can pose a danger to humans. Filtration is often very difficult as these trace substances, which are soluble in water, are so minute. Newly-developed double switchable membranes could make it possible to filter these molecules, as well as other biomolecules such as proteins and nucleic acids. The new membranes can reduce or enlarge pore size through changes in temperature and pH value.
Better cancer drugs that zero in on a tumor with fewer side effects. A universal flu vaccine that could fight every strain of influenza without needing a yearly shot. Research into potentially life-saving products like these will be delayed and newer discoveries shelved if Congress can't avert impending budget cuts that the director of the National Institutes of Health warns will have far-reaching effects.
Side effects are a major reason that drugs are taken off the market and a major reason why patients stop taking their medications, but scientists are now reporting the development of a new way to predict those adverse reactions ahead of time. The computer-based approach could save patients from severe side effects and save drug companies time and money.
Biotech giant Amgen Inc. and Belgian drugmaker UCB SA have scrapped plans for late-stage testing of an experimental treatment for accelerated healing of fractures, but will continue testing their drug for a much bigger and potentially lucrative market, treating osteoporosis in postmenopausal women.
Drug developer Eli Lilly and Co. is stopping clinical testing of an experimental rheumatoid arthritis treatment because it wasn't working. The Indianapolis company said Thursday it will continue studying the potential drug, tabalumab, as a possible treatment for a form of the autoimmune disorder lupus and the bone marrow cancer multiple myeloma.
French drugmaker Sanofi said Monday that the Food and Drug Administration will review its experimental multiple sclerosis treatment Lemtrada. Genzyme, Sanofi's U.S. biotech business, said the FDA will conduct a standard 10-month review and will make a decision on the drug in late 2013.
A series of papers published recently in the journal The Lancet are calling attention to the rapid spread of vector-borne, zoonotic diseases such as West Nile virus, dengue fever, and Lyme disease. These diseases, spread to humans by animals like mosquitos and ticks, are advancing as a result of urbanization, land use, and more intensive agricultural practices.
Researchers from North Carolina State University have increased the potency of a compound that reactivates antibiotics against methicillin-resistant Staphylococcus aureus (MRSA). Their improved compound removes the bacteria's antibiotic resistance and allows the antibiotic to once again become effective at normal dosage levels.
Using in silico computational tools to complement the results of in vivo and in vitro experiments, researchers at Pacific Northwest National Laboratory have revealed an atomic-level understanding of the mechanism by which nanoparticles inhibit the growth and metastasis of pancreatic tumors. The findings are promising for the development of particle-based therapies.
- Page 1